Septerna Raises $100M in Series A Financing


Septerna, a South San Francisco CA-based biotechnology company, raised $100M in Series A funding.

The round was led by Third Rock Ventures with participation from Samsara BioCapital, BVF Partners, Invus Financial Advisors, Catalio Capital Management, Casdin Capital and Logos Capital.

The company intends to use the funds to advance its pipeline of novel GPCR-targeted drug programs, enabled by the Native ComplexTM Platform and spanning multiple therapeutic areas, to continue to build its industrialized platform to enable drug discovery across the entire GPCR superfamily and to uncover novel mechanisms and new opportunities for previously difficult-to-drug GPCRs to address many diseases.

Led by Robert Lefkowitz, MD, co-founder, Septerna is a biotechnology company creating broad new drug discovery opportunities across many disease areas for the abundant drug target class of G protein-coupled receptors (GPCRs). The company’s Native Complex™ Platform recapitulates GPCRs with their native structure, function, and dynamics outside of the cellular environment to enable new technologies for industrial-scale drug discovery for the entire GPCR target class for the first time.

Septerna has a pipeline of GPCR-targeted small molecule drug discovery programs, along with growth potential to reach many GPCRs that have been undruggable and unexploited to date.